FivepHusion is a globally focused, advanced clinical stage, biotech company driven to optimize cancer therapy to improve patient treatment outcomes and quality of life.
Throughout our lives, each of us will either experience the trauma of cancer first-hand, or through the experiences of a family member or friend. Unfortunately, standard chemotherapy used to treat cancer often has limited therapeutic benefit, with a significant side effect burden and serious impact on quality of life.
We are developing Deflexifol™ as a replacement of sub-optimal standard of care therapy for the treatment of metastatic colorectal cancer, and other tumors with a projected global incidence of greater than 6 million patients. Deflexifol™ is also being developed as a new therapy for cancers with high unmet medical need, such as pediatric ependymoma; a rare and deadly brain cancer which afflicts very young children.
Company Details
- Employees
- 5
- Founded
- -
- Address
- Sydney, Nsw 2037, Au
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://fivephusion.com/
- Keywords
- drug development, oncology, biotechnology, science, colorectal cancer, brain cancer, pharmaceuticals, clinical trials, research.
- HQ
- Sydney, NSW
Fivephusion Questions
Fivephusion's website is http://fivephusion.com/
Fivephusion's LinkedIn profile is https://au.linkedin.com/company/fivephusion
Fivephusion has
5 employees.
View email and phone details for 5
employees at Fivephusion.
Fivephusion's industry is
Biotechnology Research
Fivephusion's top competitors are
Chosa Oncology,
Mimetic - Medtech Foundry,
Celosia Therapeutics,
Aphex Pharma Solutions,
Bionsw,
Bio-Link Australia Pty. Ltd.,
Race Oncology,
Actinogen Medical,
Imugene Limited,
Amplia Therapeutics Limited.
Fivephusion's categories are Biotechnology Research
Fivephusion's founding year is 2018
